SCHEMBL7033347

SCHEMBL7033347

O=CC1=C(c2ccccc2)c2ccccc2OC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 8/20 0.43
KMT2A Q03164 2/20 0.41
THRB P10828 1/20 0.40
PKM P14618 2/20 0.38
TSHR P16473 1/20 0.38
NTSR1 P30989 1/20 0.38
GPR55 Q9Y2T6 1/20 0.38
ALDH1A1 P00352 4/20 0.37
MAPT P10636 4/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MITF O75030 1/20 0.37
HTT P42858 1/20 0.37
KDM4E B2RXH2 3/20 0.37
GAA P10253 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
HPGD P15428 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20629314 0.82 ALDH1A1 (0.49) MAOBKMT2AALDH1A1MAPTRAB9A
SCHEMBL7224651 0.80 ESR1 (0.51) MAOBKMT2ATHRBALDH1A1MAPT
SCHEMBL7232088 0.77 PAM (0.43) MAOBKMT2ATHRBALDH1A1KDM4E
SCHEMBL9376747 0.76 MAOB (0.44) MAOBKMT2APKMTSHRALDH1A1
SCHEMBL9370825 0.76 MAOB (0.41) MAOBKMT2APKMTSHRALDH1A1
SCHEMBL7030875 0.76 MAOB (0.41) MAOBKMT2APKMTSHRALDH1A1
SCHEMBL3607151 0.74 ESR1 (0.41) KMT2APKMALDH1A1MAPTHTT
SCHEMBL3607145 0.74 ESR1 (0.41) KMT2APKMALDH1A1MAPTHTT
SCHEMBL16139564 0.72 CES1 (0.44) MAOBPKMALDH1A1MAPTSMN1; SMN2
SCHEMBL21294262 0.72 THRB (0.46) KMT2ATHRBPKMALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107454902-B Chromene derivatives as phosphoinositide 3-kinase inhibitors 奇斯药制品公司 2020-09-15 CN disclosed
EP-3283481-B1 CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARM SPA (IT) 2019-03-13 EP disclosed
EP-3283481-B1 CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARM SPA (IT) 2019-03-13 EP disclosed
US-9968604-B2 Chromene derivatives as phoshoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2018-05-15 US disclosed
US-9968604-B2 Chromene derivatives as phoshoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2018-05-15 US disclosed
US-9968604-B2 Chromene derivatives as phoshoinositide 3-kinases inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2018-05-15 US disclosed
EP-3283481-A1 CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2018-02-21 EP disclosed
US-20160303123-A1 CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2016-10-20 US disclosed
WO-2016166239-A1 CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2016-10-20 WO disclosed
US-20160303123-A1 CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2016-10-20 US disclosed
WO-2016166239-A1 CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2016-10-20 WO disclosed
US-6596758-B1 Treatment of dislipidaemias, atherosclerosis and diabetes, to pharmaceutical compositions comprising them and to processes allowing the preparation of these compounds. MERCK PATENT GMBH (DE) 2003-07-22 US disclosed
EP-1140893-B1 BENZOPYRANS AND BENZOXEPINES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PREPARATION PROCESS MERCK PATENT GMBH (DE) 2003-03-05 EP disclosed
US-6509362-B2 Cholesteryl acyl transferase (ACAT) inhibitors; treatment of hyperlipidaemia and atherosclerosis. MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2003-01-21 US disclosed
US-20020068739-A1 New N-phenylamide and N-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2002-06-06 US disclosed
US-6339097-B1 FOR THERAPY OF HYPERLIPIDAEMIA AND ATHEROSCLEROSIS; CHOLESTERYL ACYL TRANSFERASE (ACAT) INHIBITORS MERCK PATENT GMBH (DE) 2002-01-15 US disclosed
EP-1140893-A1 BENZOPYRANS AND BENZOXEPINES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PREPARATION PROCESS MERCK PATENT GmbH (DE) 2001-10-10 EP disclosed
EP-1040109-A1 N-PHENYLAMIDE AND N-PYRIDYLAMIDE DERIVATIVES, METHOD OF PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM MERCK PATENT GmbH (DE) 2000-10-04 EP disclosed
WO-2000039113-A1 BENZOPYRANS AND BENZOXEPINES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND PREPARATION PROCESS MERCK PATENT GMBH (DE) 2000-07-06 WO disclosed
WO-1999033825-A1 N-PHENYLAMIDE AND N-PYRIDYLAMIDE DERIVATIVES, METHOD OF PREPARING THEM AND PHARMACEUTICAL COMPOSITONS CONTAINING THEM MERCK PATENT GMBH (DE) 1999-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068739-A1 New N-phenylamide and N-pyridylamide derivatives, method of preparing them and pharmaceutical compositions containing them ACAT2, LCAT, ACAT1 MAOB 293/4885KMT2A 884/4885THRB 3341/4885
US-20160303123-A1 CHROMENE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS PIKFYVE, PI4KA, PIP4K2B MAOB 3153/4885KMT2A 4009/4885THRB 2047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.